Technologies Driving Precision Medicine

Emerging Role of Chimeric Antigen Receptor (CAR) T-cell Treatment and Bispecific/Multi-specific T-cell Engaging Antibody Therapies

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects.
This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.

Table of Contents

1.0 Executive Summary1.1 Research Scope1.2 Research Methodology1.2 Research Methodology (Continued)1.3 Key Findings2.0 Technologies Driving CAR T-cell Therapy2.1 CAR T-cell Therapies Ideally Poised to Transform the Global Immunotherapy Landscape2.2 CART Therapy Enables Improved Efficacy, Although Adverse Events May Continue to be a Cause For Concern2.3 Antigen Identification and Enhanced Clinical Response are the Key Technology Drivers2.4 Key Technology Restraints Comprise Critical Adverse Events and Reduced Efficacy in Solid Tumors3.0 Analysis of Research, Funding, Clinical, and IP Landscapes3.1 CAR T-cell Therapy Garners Growing Attention Across Research3.2 Cancer Constitutes the Top Application Area For NIH-funded CAR T Therapy Projects3.3 China Leads Global Clinical Trial Landscape Involving CAR T-cells3.4 China Leads the Global Patent Landscape For CAR T-cell-based Innovations4.0 Industry Trends and Future Perspectives for CAR T Therapies4.1 Comparative Analysis of CAR T Platforms in Solid and Hematological Cancers4.2 Transforming Immunotherapy With CAR T Technologies4.3 Overview of Key CAR T Innovators4.4 Future of CAR T Platform5.0 Emerging Technological Landscape For Bispecific/Multi-specific Antibodies5.1 Development of Bispecific/Multi-specific Antibody Platforms For Enhanced Therapeutic Applications5.2 Bispecific/Multi-specific Platforms Offer Enhanced Therapeutic Benefits5.3 Novel Antibody Platforms Improve Treatment Efficacy5.4 Immunotoxicity Concerns Limit the Development of Bispecific/Multi-specific Antibody Platforms6.0 Analysis of Research, Funding, Clinical, and IP Landscape6.1 Growing Research Trends in Bispecific Antibody Platforms6.2 Cancer is the Top Funding Area For NIH Projects Related to Bispecific/Multi-specific Therapeutic Antibodies6.3 Most Clinical Studies For Bispecific/Multi-specific Antibodies Are Still in Early Phase6.4 US Leads the IP Landscape For Innovations in Bispecific/Multi-specific Platforms7.0 Industry Developments Across Bispecific and Multi-specific Antibody Therapeutics7.1 Bispecific Antibody Treatment Platforms Score Over Conventional Monotherapies7.2 Key Innovators Across Bispecific Therapies7.3 Key Innovators Across Bispecific and Multi-specific Therapies8.0 Growth Opportunities and Companies to Action8.1 Growth Opportunity 1: Molecular Profiling Platforms8.2 Growth Opportunity 2: CAR T-cell Therapy8.3 Growth Opportunity 3: Bispecific/Multi-specific Antibodies8.4 Strategic Imperatives for Success and Growth 9.0 Appendix9.1 Summary of Key Contacts9.1 Summary of Key Contacts (continued)Legal Disclaimer




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.